Q32 Bio Inc.
HealthcareNASDAQ:QTTB · NASDAQ Global Market
-$0.06 today
Vol 0.33M · Avg 0.74M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$53.7M of revenue converted into $33.2M of net income for the selected period. Gross margin is 25.0% and net margin is 26.9%, showing how much revenue survives after costs and taxes. EPS is $2.66, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $0 +100.0% | -$6.7M -200.0% | $6.7M -80.4% | $34.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $391.0K -19.7% | $487.0K | $0 | $0 -100.0% | $9.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $53.3M +11054.0% | -$487.0K +92.7% | -$6.7M -200.0% | $6.7M -72.8% | $24.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 99.3% | — | 100.0% +0.0pp | 100.0% +28.1pp | 71.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $19.2M -60.2% | $48.1M +51.7% | $31.7M -11.4% | $35.8M -61.5% | $93.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.7M +1.2% | $17.5M +76.9% | $9.9M -1.9% | $10.1M -63.1% | $27.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $36.4M -44.5% | $65.6M +57.7% | $41.6M -9.3% | $45.9M -61.9% | $120.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $391.0K -19.7% | $487.0K -2.4% | $499.0K +34.9% | $370.0K -96.1% | $9.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $17.3M +138.2% | -$45.3M +5.1% | -$47.8M -22.9% | -$38.9M +54.9% | -$86.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 32.2% | — | 718.0% +1302.2pp | -584.2% -330.4pp | -253.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $16.9M +125.6% | -$66.1M -37.0% | -$48.3M -23.0% | -$39.2M +59.1% | -$95.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 31.5% | — | 725.5% +1315.3pp | -589.8% -307.3pp | -282.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.2M -43.6% | $3.9M | $0 | $0 -100.0% | $185.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.1M +266.7% | $300.0K | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.9M -29.7% | $18.4M +455.7% | -$5.2M -46.8% | -$3.5M -2003.8% | $185.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $29.8M +162.5% | -$47.7M +10.7% | -$53.4M -25.0% | -$42.7M +55.4% | -$95.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 55.5% | — | 803.3% +1446.0pp | -642.7% -360.8pp | -281.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 -100.0% | $21.0K -93.4% | $318.0K +412.9% | $62.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $29.8M +162.5% | -$47.7M +11.2% | -$53.7M -25.5% | -$42.8M +55.3% | -$95.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | 55.5% | — | 808.0% +1451.7pp | -643.6% -361.7pp | -281.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +147.3% | -$5 +69.3% | -$17 -24.4% | -$13 +57.0% | -$31 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +136.8% | -$7 +60.6% | -$17 -24.4% | -$13 +57.0% | -$31 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $12.3M +0.8% | $12.2M +279.0% | $3.2M +0.9% | $3.2M +3.8% | $3.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $12.3M +1.0% | $12.2M +279.0% | $3.2M +0.9% | $3.2M +3.8% | $3.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
$61.03M
Generation Bio Co.
GBIO
$35.98M
SAB Biotherapeutics, Inc.
SABS
$31.83M
Boundless Bio, Inc.
BOLD
$31.67M
Plus Therapeutics, Inc.
PSTV
$12.12M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
Intensity Therapeutics, Inc.
INTS
$6.83M
NextCure, Inc.
NXTC
$5.56M
Iterum Therapeutics plc
ITRM
$1.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does QTTB generate?
Q32 Bio Inc. (QTTB) reported $53.74M of revenue in fiscal 2025.
Is QTTB profitable?
Q32 Bio Inc. (QTTB) reported $29.82M of net income, with a net margin of 55.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.